MeiraGTx Holdings Plc (MGTX)
10.88
-0.16
(-1.49%)
USD |
NASDAQ |
Sep 25, 16:00
10.88
0.00 (0.00%)
After-Hours: 19:59
MeiraGTx Holdings Research and Development Expense (Annual) : 129.32M for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | 129.32M |
| December 31, 2024 | 119.18M |
| December 31, 2023 | 103.48M |
| December 31, 2022 | 85.52M |
| December 31, 2021 | 66.83M |
| Date | Value |
|---|---|
| December 31, 2020 | 33.91M |
| December 31, 2019 | 24.88M |
| December 31, 2018 | 33.62M |
| December 31, 2017 | 22.36M |
| December 31, 2016 | 14.04M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| Xencor, Inc. | 239.43M |
| UroGen Pharma Ltd. | 67.11M |
| Ironwood Pharmaceuticals, Inc. | 93.26M |
| Viking Therapeutics, Inc. | 344.96M |
| IDEAYA Biosciences, Inc. | 314.70M |